Legend Biotech CEO to Discuss Strategy at Morgan Stanley Healthcare Conference
Event summary
- Alan Bash, interim CEO of Legend Biotech, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on September 15, 2026.
- The event will be webcast live and replay available 48 hours later.
- Legend Biotech has over 3,000 employees and is a leader in CAR-T cell therapy.
- The company markets CARVYKTI® in collaboration with Johnson & Johnson.
The big picture
Legend Biotech's participation in the Morgan Stanley Global Healthcare Conference comes at a critical juncture for the cell therapy sector, where CAR-T therapies are increasingly becoming mainstream treatments for multiple myeloma. The company's collaboration with Johnson & Johnson on CARVYKTI positions it as a key player, but it must navigate a competitive landscape and demonstrate sustained innovation to maintain its leadership. The event provides a platform for interim CEO Alan Bash to outline the company's strategic direction and address investor concerns about its future growth prospects.
What we're watching
- Strategic Vision
- How Alan Bash will articulate Legend Biotech's long-term strategy amid competitive pressures in the cell therapy space.
- Pipeline Expansion
- Whether the company can sustain innovation across its pipeline of cutting-edge cell therapy modalities.
- Market Positioning
- The pace at which Legend Biotech can maximize CARVYKTI’s patient access and therapeutic potential.
Related topics